Tiziana Life Sciences PLC (TLSA) stock prices were down by 0.60% as of the market closing on September 1st 2021. This brought the price per share down to USD$1.65 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 15.76%, bringing it up to USD$1.92.
TLSA Stock Collaborates with Precision
September 2nd 2021 saw TLSA stock announced an exclusive license agreement with Precision Biosciences. The agreement will facilitate the exploration of the company’s foralumab as an agent to induce tolerance of allogeneic CAR T cells. The fully human anti-CD3 monoclonal antibody (mAb) could potentially improve the clinical outcome of CAR T cell therapy.
CAR T Cell Therapy
The Cluster of Differentiation (CD) 3 is a receptor on effector T cells. An anti-CD3 antibody has the potential to eliminate or tolerize patient effector T cells. TLSA stock’s manufacturing process utilizes ARCUS to knock out the TRAC gene, after which it implements a CD3-depletion step. This produces allogeneic CAR T candidates that are more than 99.9% CD3-negative. Accordingly, an anti-CD3 antibody such as foralumab could be used to enable CAR T cells to expand, proliferate, and persist to maximize long term clinical benefits.
Exclusive Foramulab License
As per the agreement, Precision will gain an exclusive license for foralumab. The treatment will serve as a lymphodepletion agent in tandem with its allogeneic CAR T therapeutics for the treatment of carious cancers. Precision will be responsible for the development, commercialization, and expenses for the use of its treatment. TLSA stock will receive upfront payment, certain milestone payments, and royalties for foramulab.
Scope of TLSA Stock’s Partnership
The companies’ collaboration to explore furamulab will result in executing potential lymphodepletion strategy with their allogeneic CAR T programs. Despite being clinically successful, relapse rates for CAR T therapies have remained high. This has been problematic in its capacity to limit broad utility, which it continues to do. Precision is keen to leverage its novel approaches to CAR T development, thereby offering the potential for meaningful off-the-shelf solutions.
Future Outlook for TLSA Stock
The company reported a promising quarter, culminating with the announcement of TLSA stock’s collaboration with Precision. TLSA is poised to capitalize on the opportunities presented to it as a result of its partnership, with both companies keen to drive the accelerated commercialization and proliferation of foramulab. Current and potential investors are confident in management’s ability to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.
